DNA
Ginkgo Bioworks Holdings, Inc.
NYSE · USHealthcareBiotechnology
$7.55-4.55%
Price as of Jul 20, 2026
DNA profitability
Ginkgo Bioworks Holdings, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 75.0%
- EBITDA margin
- -149.2%
- EBIT margin
- -210.7%
- Net margin
- -215.4%
- Free cash flow margin
- -129.7%
Returns
- Return on equity
- -68.7%
- Return on assets
- -29.5%
- Return on invested capital
- -34.9%
- Asset turnover
- 0.13x
Cash efficiency
- Cash from operations
- -$166.0M
- Cash per share
- $5.72
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.